Please use this identifier to cite or link to this item:
|Title:||DNA double strand break assessment as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor radiotherapy|
|Authors:||GRAF Franziska; FAHRER Jörg; MAUS Stephan; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; VENKATACHALAM S.; FOTTNER C.; WEBER Matthias M.; HUELSENBECK Johannes; SCHRECKENBERGER M; KAINA B; MIEDERER Matthias|
|Citation:||EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 40 no. S2 p. S107|
|Type:||Articles in periodicals and books|
|Abstract:||Alpha-particle emitters display high linear energy transfer combined with short range and are promising for treatment of tumor micrometastases. Indeed, efficiency and high specificity of tumor-specific antibodies labeled with alpha emitting nuclides were described in vitro and in vivo. Radiolabeled somatostatin analogues with high affinity to somatostatin receptor overexpressing tumors are an attractive option for peptide-receptor radionuclide therapy of metastasized neuroendocrine tumors and great clinical success has been demonstrated with Lutetium-177 as therapeutic isotope. In this study, we investigated cellular effects of alpha-particle emitter Actinium-225 in comparison to beta-particle emitter Lutetium-177 labeled somatostatin analogue DOTATOC in vitro and in vivo. Cellular studies were performed in p53 dependent and somatostatin receptor expressing rat pancreatic acinar carcinoma AR42J cells.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.